ESMO 2024 – Scorpion joins Relay in the alpha club
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.